CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on improving the production of CAR-T cell therapies for cancer treatment by utilizing ImmunoGrow technology, which enhances cell yield and reduces manufacturing costs. The goal is to make these life-saving treatments more accessible to patients by streamlining the production process.
Lifesaving cell-based CAR-T therapies have achieved remission rates of up to 83% for patients with the most aggressive and untreatable cancers.
These therapies harness a patient’s own genetically engineered immune cells to target cancer cells.
However, manufacturers are struggling to produce these individualised treatments at scale resulting in prohibitive prices as high as $475,000 per treatment.
Unless solutions that address these limitations are provided, publically-funded EU healthcare syste…
Grey Matter Technologies Limited
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
